Browsing by Subject "NECROSIS-FACTOR-ALPHA"

Now showing 1 - 10 of 10
  • No Thumbnail Available
    Item
    Evaluation of metabolic syndrome in patients with chronic low back pain
    (SPRINGER HEIDELBERG) Duruöz, MT; Turan, Y; Gürgan, A; Deveci, H
    The aim of our study was to investigate the frequency of the metabolic syndrome in chronic low back pain and evaluate the differences in clinical and functional parameters in chronic low back pain patients with and without metabolic syndrome. Patients complaining of low back pain complaint lasting for at least 2 months were included in the study. In order to establish functional deficiency, Roland-Morris Disability Questionnaire, Istanbul Low Back Pain Disability Index and Oswestry Disability Index were used. To evaluate depression, Beck's depression scale was used. The diagnosis of metabolic syndrome was made according to the criteria of National Cholesterol Education Program (NCEP) defined in 2001. For this; lumbar circumference around anterior iliac spine, arterial blood pressure, fasting blood glucose, plasma triglyceride levels and HDL cholesterol levels were noted down. Sixty patients (51 women) were included in the study. There was significant difference in terms of BMI (P = 0.034), age (P = 0.001), waist circumference (P = 0.048) and disease duration (P = 0.005) between chronic low back pain patients with and without metabolic syndrome. There was no significant difference in other parameters. Low back pain is a frequent complaint amongst people with obesity in the abdominal area. According to our results, elderly people, people with chronic low back pain and patients with high BMI are under risk for metabolic syndrome. For this reason this group of patients can be screened for metabolic syndrome and preventive measures can be taken.
  • No Thumbnail Available
    Item
    Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-α, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis
    (JOHN LIBBEY EUROTEXT LTD) Özmen, B; Kirmaz, C; Aydin, K; Kafesciler, SO; Guclu, F; Hekimsoy, Z
    Background. Osteoporosis that is encountered frequently in postmenopausal women, may cause an increased incidence of vertebral and iliac fractures that are associated with excess morbidity. Raloxifene hydrochloride, a selective oestrogen receptor modulator, has been shown to increase bone mineral density and decrease biochemical markers of bone turnover in postmenopausal women, without stimulatory effects on breast or uterus. Levels of proinflammatory cytokines, including IL-6, and TNF-alpha and TGF-beta 1 which are important cytokines involved in remodeling, have been evaluated previously in in vitro studies of osteoporosis. However, there seems to be a paucity of in vivo research concerned with changes in these cytokines in osteoporosis. Objective. In this study, we evaluated the effects of raloxifene (Evista (R); Lilly Pharmaceutical Co. USA, 60 mg/day) on biochemical bone turnover markers, serum parathyroid hormone, and 25-OH vitamin D, as well as the serum levels of IL-6, TNF-alpha and TGF-beta 1, in 22 postmenopausal, osteoporotic women before and after 12 weeks of raloxifene treatment. Methods. Well-matched, postmenopausal, non-osteoporotic control subjects were also enrolled in the study. Serum levels of all the parameters were measured in postmenopausal, osteoporotic women at baseline and end of the study. Results. It was found that serum osteocalcin and parathyroid hormone, and urine deoxypyridinoline levels decreased to normal levels with treatment. Serum 25-OH vitamin D levels after treatment in the patient group were higher than those in the control group. Serum IL-6, TNF-alpha and TGF-beta 1 levels did not change significantly with treatment. However, serum levels of IL-6 and TGF-beta 1 in the patient group after treatment, decreased to levels lower than those found in the control group. Serum TNF-alpha levels in the patient group before and after treatment, were lower than those in the control group. Conclusion. Raloxifene treatment reduces bone turnover biochemical markers, parathyroid hormone and induces 25-OH vitamin D in postmenopausal women. Moreover, it also affects some serum cytokine levels in the postmenopausal period.
  • No Thumbnail Available
    Item
    Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique
    (CLINICAL & EXPER RHEUMATOLOGY) Distler, JHW; Jordan, S; Airò, P; Alegre-Sancho, JJ; Allanore, Y; Gurman, AB; Caporali, R; Caramaschi, P; Carreira, PE; Chizzolini, C; Cutolo, M; Duruöz, MT; Farge-Bancel, D; Hesselstrand, R; Iannone, F; De Keyser, F; Kucharz, EJ; Launay, D; Lefebvre, PGD; Lukacova, O; Marasini, B; Martinovic, D; Neto, JFM; Radic, M; Rednic, S; Riemekasten, G; Rovensky, J; Seidel, MF; Senel, S; Smith, V; Sunderkötter, C; Ton, E; van Laar, JM; Matucci-Cerinic, M; Müller-Ladner, U; Distler, O
    Objective: To obtain experiences and expert opinion on treatment of SSc patients with TNF-alpha antagonists. Methods: An investigation was carried out among the EUSTAR centres into their expertise on use of TNF-alpha antagonists. Assessment forms on the frequency of TNF-alpha inhibitor use were distributed to EULAR Scleroderma Trials and Research Group (EUSTAR) centres. Afterwards, a three round Delphi exercise was performed to obtain expert consensus on the use of TNF-alpha inhibitors in SSc. Results: Seventy-nine centres returned information on use of TNF-alpha antagonists in SSc patients. A total of 65 patients were treated with TNF-alpha inhibitors in 14 different centres. Forty-eight of the 65 patients treated with TNF-alpha inhibitors improved. Improvement was mainly seen in patients with arthritis, whereas the effects on fibrosis varied. In the first round of the subsequent Delphi approach, 71 out of 79 experts stated that they would use TNF-alpha antagonists in SSc. Arthritis was suggested as an indication for TNF alpha antagonists by 75% of the experts. However; after the third stage of the Delphi exercise, the acceptance for the off-label use of TNF-alpha antagonists decreased and 59% recommended that TNF-alpha antagonists should not be used or only used in clinical trials in SSc patients, while 38% of the experts suggested the use of TNF-alpha antagonists for arthritis associated with SSc. Conclusions: Most of the experts do not recommend the routine use of TNF-alpha antagonists in systemic sclerosis. Arthritis might be a potential indication in SSc, although controlled clinical trials with TNF-alpha antagonists are needed before general recommendations can be given.
  • No Thumbnail Available
    Item
    Jak-Stat signaling pathway may play a role in the pathogenesis of cholesteatoma
    (W B SAUNDERS CO-ELSEVIER INC) Eskiizmir, G; Vatanseuer, HS; Özgür, E; Aslan, A; Tanyeri, G; Gözüaçik, D; Özbilgin, MK; Cingi, C
    Purpose: Jak-Stat signaling pathway is one of the major signal transduction cascades which regulates most of the cellular events such as cell proliferation, differentiation, cell migration and apoptosis. This study aims to determine the activity of Jak-Stat signaling pathway in the pathogenesis of cholesteatoma. Materials and Methods: Cholesteatoma and skin samples were obtained from 10 patients who underwent tympanomastoidectomy for chronic otitis media with cholesteatoma. Immunohistochemical analysis of cholesteatoma and skin was performed using anti-Jak1, anti-Jak2, anti-Jak3, anti-Stat1, anti-Stat2, anti-Stat3, anti-Stat4 and anti-Stat5 antibodies. The immunoreactivities in cholesteatoma and skin were quantified using H-score measurement and statistical comparison was performed. Results: Jak1, Jak2, Jak3, Stat1 and Stat3 immunoreactivities were not detected in cholesteatoma; in contrast to the skin (129.8; 226.7; 33.0; 66.4;115.9). In addition, when H-score measurements of Stat2, Stat4 and Stat5 immunoreactivities were compared between cholesteatoma (172.8; 166.7; 120.0) and skin (400.0; 284.9; 292.0), statistically significant differences were found (p < 0.0001, p < 0.0001, p < 0.0001). Conclusions: A remarkable deficiency in the family members of Jak-Stat signaling pathway was demonstrated in cholesteatoma. Therefore, perturbations in Jak-Stat signaling pathway may play a role in the pathogenesis of cholesteatoma. (C) 2014 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    The effect of Vortioxetine on the NLRP3 pathway and microglial activity in the prefrontal cortex in an experimental model of depression
    (TAYLOR & FRANCIS LTD) Unal, GO; Kumbul, D; Ozturk, KH; Erkilinc, G; Donmez, F; Kiran, ED; Yuceer, RO
    BackgroundIncreasing evidence suggests that early life stress (ELS) and neuroinflammation are associated with the pathophysiology of depression. The purpose of this study was to determine the effects of Vortioxetine (VOR), a novel antidepressant, on ELS-induced behavioral changes and neuroinflammation.MethodWistar Albino 4-week-old male rats were divided into four groups: control; chronic unpredictable stress (CUMS), VOR, CUMS + VOR. Neurobehavioral assessment was performed on the first, 21st, and 42nd days. RT-PCR was used to detect the expression of P2X7, NLRP3, IL1 beta, IL18 in the prefrontal cortex. To assess the microglial activities of the prefrontal cortex, immunohistochemically stained CD68, and leukocyte common antigen (LCA) preparations were scanned with Manual WSI software, Basler camera, and scored.Result and discussionExposure to CUMS was associated with depression and anxiety-like behaviors, and administration of VOR led to improvement in these behaviors. NLRP3, IL-1 beta, and IL-18 were shown to be upregulated in the prefrontal cortex of CUMS rats, while their high expression was inhibited by VOR treatment. CD68 and LCA expressions were significantly higher in the CUMS group compared to the other groups.ConclusionAccording to these results, it may be considered that NLRP3 inflammasome-associated neuroinflammatory response and microglial activation may play a role in the etiopathogenesis of ELS.
  • No Thumbnail Available
    Item
    Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review
    (KOREAN SOC OTORHINOLARYNGOL) Uz, U; Eskiizmir, G
    Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of cancer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant benefits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HNSCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysis demonstrated that overexpression and elevated serum and/or saliva 1L-6 concentrations in patients with HNSCC are related to poor survival and oncological outcomes. Although there is a correlation between IL-6 concentrations and tumorigenicity, it is noteworthy that IL-6 targeted therapies are generally performed in vitro and in experimental studies.Therefore, prospective, randomized clinical trials are required that focus on IL-6 targeted therapies for the treatment of HNSCC.
  • No Thumbnail Available
    Item
    Adiponectin Levels in Gestational Diabetes Mellitus and in Pregnant Women Without Glucose Intolerance
    (WROCLAW MEDICAL UNIV) Pala, HG; Ozalp, Y; Yener, AS; Gerceklioglu, G; Uysal, S; Onvural, A
    Objectives. The aim of the study was to determine serum adiponectin levels among patients with gestational diabetes mellitus (GDM) and normal pregnant women without glucose intolerance, and to investigate the relationship between these levels and clinical factors at the time of the diagnosis, at delivery and in the post-partum period. Material and Methods. The subjects' serum adiponectin concentration was measured using the enzyme-linked immunosorbent assay (ELISA) method at 24th-28th week of gestation, at delivery (in maternal circulation and the umbilical cord) and 24 h after delivery. The relationship between these groups' measurements and other established clinical-laboratory factors were investigated. Results. Serum adiponectin concentrations were significantly lower (p = 0.02) in GDM patients compared with patients with normal glucose tolerance at 24th-28th week of gestation. During delivery, maternal serum adiponectin concentrations were significantly lower (p = 0.03) in GDM patients compared with patients with normal glucose tolerance. In the post-partum period, serum adiponectin concentrations were significantly higher (p = 0.009) in GDM patients compared with patients with normal glucose tolerance. Umbilical cord adiponectin concentrations were significantly lower (p = 0.005) in GDM patients compared with patients with normal glucose tolerance. Conclusions. Adiponectin concentrations in GDM patients' circulation were regulated by changes in glucose and insulin metabolism. A reduction in serum adiponectin levels seems to play a role in GDM patients' insulin resistance
  • No Thumbnail Available
    Item
    Treatment of Severe Asthma: Expert Opinion
    (TURKISH ASSOC TUBERCULOSIS & THORAX) Türktas, H; Bavbek, S; Çelik, G; Demir, T; Gemicioglu, B; Günen, H; Kiyan, E; Mungan, D; Oguzulgen, IK; Polatli, M; Saryal, S; Sayiner, A; Sen, E; Yildirim, N; Yildiz, F; Yorgancioglu, A
    Severe asthmatics account 10% of the all asthmatic population. Those asthmatics whose disease is inadequately controlled account for up to half of the cost for asthma, because they have more emergency room visits, more hospital admission and greater absenteeism from work. New therapeutic options were tried in those patients whose asthma was uncontrolled with standart high dose inhaled corticosteroid and long acting beta-2 agonsit combination therapy. In this paper taking into account the conditions of our country, current literature was reviewed and treatment options was discussed and graded recommendations are made for daily clinical practice in patients with severe treatment-refractory asthma.
  • No Thumbnail Available
    Item
    Preoperative Oral Pentoxifylline for Management of Cytokine Reactions in Cardiac Surgery
    (FORUM MULTIMEDIA PUBLISHING, LLC) Iskesen, I; Kurdal, AT; Kahraman, N; Cerrahoglu, M; Sirin, BH
    Background: Cardiopulmonary bypass may lead to many inflammatory responses that may cause myocardial dysfunction after open heart surgery. We aimed to investigate the effect of preoperative pentoxifylline treatment to reduce the occurrence of cardiopulmonary bypass-induced inflammatory response. Methods: In a prospective, randomized study, 40 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (study group, n = 21) or not (control group, n = 19). Pretreatment with pentoxifylline (800 mg/day orally) was started 5 days before the operation. Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8 from the arterial line, and venous blood samples for creatine kinase (CK) and CK isoenzyme fraction MB (CK-MB) were taken in both groups at 5 different time points. Hemodynamic parameters were measured with the thermodilution technique. Results: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a greater increase in the control group (P < .05). There were no significant differences between the groups for the values of CK-MB and hemodynamic parameters. Conclusions: We conclude that pretreatment with oral pentoxifylline before cardiac surgery inhibits proinflammatory cytokine release caused by cardiopulmonary bypass and has some beneficial effects in protecting the myocardium during the cardioplegic arrest period in open-heart surgery, without affecting postoperative hemodynamics.
  • No Thumbnail Available
    Item
    IL-2R, IL-6 and IL-8 Levels in Behcet's Disease
    (DERI ZUHREVI HASTALIKLAR DERNEGI) Inanir, I; Onur, E; Pirildar, T; Gündüz, K; Var, A
    Background and Design: Immunological factors are considered to have an important role in the multifactorial ethiopathogenesis of Behcet's disease (BD). Especially, Th1 cells function by expressing proinflammatory cytokines and neutrophil-attracting chemokines. Levels of IL-2R, IL-6 and IL-8 were evaluated in patients with BD in this study. Material and Method: Sixty-six patients with BD (36 with inactive and 30 with active) composed the study group and 22 subjects the control group. Cytokine analyses were done with ELISA method by using commercial kits. ESR and CRP levels were also measured. Results: IL-2R, IL-6 and IL-8 levels in all patients, including the inactive ones, were not different from those in controls. CRP and ESR levels in patients were higher than in controls. IL-8 and CRP levels were increased in patient with active BD (p<0.05) when compared to those with inactive BD. Conclusion: Our study demonstrated elevated levels of serum IL-8, a chemokine activating monunuclear cells and neutrophils, in patients with active BD. IL-8 may be considered as an activity marker for BD. (Turkderm 2010; 44: 213-5)